开学福利来啦！打印机、听力机超值捡漏！ 预约直播，助娃学习更轻松 最近《一路繁花2》热播， 让张柏Z的风评好到爆，一颦一笑间不见疲态，状态好到根本看不出来姐今年已经45岁了。 洞见 （DJ00123987） ——不一样的观点，不一样的故事，3000万人订阅的微信大号。点击标题下蓝字"洞见"关注，我们将为您提供有价值、有意 思的延伸阅读。 唯独眼周，30+就逐渐出现 眼窝凹陷、眼尾下垂、泪沟、眼周皱纹等衰老症状 ，看起来又老又疲惫。 但凡 秋冬没做好护肤， 细纹 & 干纹立马蹬鼻子上眼， 遮瑕 + 粉底都盖不住 ，憔悴感溢出了屏幕。 更别说，长期带娃的宝妈，三班倒的姐妹 ，鱼尾纹、眉间纹…… 早就在眼周组团安了家。 网友直呼： " 45美成20岁，太嫩了！""震撼！果然明星就是一秒回春……" 作为骨相颜值代表，张柏Z的面部状态一直都不错。 我自己都记不清，用过多少不同品牌的眼霜产品。 其中很多也都是主打奢华贵妇成分，或者有 黑科技助攻 的， 但是效果往往 昙花一现，典型治标不治本。 而且确实很贵，换言之，差强人意。 寻找一款 性价比高，安全、好用的眼霜 ，就成了比较重要的任务了。 姐妹们， 眼周的保养越早做越好 ...

漳州片仔癀药业股份有限公司 证券代码：600436 证券简称：片仔癀 公告编号：2026-008 漳州片仔癀药业股份有限公司 关于选举第七届董事会职工董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《公司法》及《公司章程》等有关规定，漳州片仔癀药 业股份有限公司（以下简称"公司"）于近期召开职工代表大会， 选举许式彬先生（简历见附件）为第七届董事会职工董事。许式 彬先生任期与公司第七届董事会任期一致。 本次选举职工董事不会导致公司董事会中兼任公司高级管 理人员以及由职工代表担任的董事人数超过公司董事总数的二 分之一，符合相关法律法规、规范性文件及《公司章程》的规定。 特此公告。 董 事 会 2026 年 3 月 2 日 1 / 2 附：许式彬先生个人简历 许式彬，男，汉族，1972 年 5 月出生，中共党员，中央党 校大学，工程师。1993 年 8 月参加工作；2016 年 10 月至 2022 年 7 月，历任漳州城投建材集团有限公司总经理、董事长；2022 年 7 月至 2024 年 1 月，任福建省漳州信 ...

Industry Overview - The Chinese medicine industry is entering a new evidence-driven cycle following the release of the Basic Drug Directory Management Measures, which emphasizes the integration of clinical value, insurance payment capabilities, and tiered diagnosis and treatment systems [8][10] - The market performance of the Chinese medicine sector showed a decline of 1.75% in the week before the holiday, which was the largest drop among the pharmaceutical sub-sectors [3][4] Market Performance - The Chinese medicine sector's PE (ttm) was 27X, down 0.49X from the previous period, while the PB (lf) was 2.27X, down 0.04X, indicating a relative valuation position within historical ranges [5] - The overall pharmaceutical sector index closed at 8282.27 points, down 0.81%, with only the medical services sector showing an increase of 0.22% [3] Upstream Market Dynamics - The market demand for Chinese medicinal materials has increased ahead of the holiday, leading to a slight rise in the price index, which reached 229.02 points, up 0.1% from the previous week [6][7] Regulatory Changes - The revised Basic Drug Directory Management Measures highlight a "balanced approach to Chinese and Western medicine," establishing a strict negative list for market entry and emphasizing clinical value and dynamic adjustments [9] - The new measures are expected to accelerate structural differentiation in the short term and favor leading companies with clinical evidence and strong innovation capabilities in the long term [8][10] Investment Recommendations - The report maintains an "overweight" rating for the industry, suggesting three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [11] - Price governance will lead to clearer differentiation within the industry, with companies that have competitive advantages likely to benefit from price-volume trade-offs [12] - The recovery of consumption driven by macroeconomic improvement and increased health awareness among the aging population is expected to boost sales of consumer-oriented Chinese medicines [13] - State-owned enterprises in the Chinese medicine sector are anticipated to benefit from reforms aimed at improving efficiency and performance [13] Target Companies - Recommended companies include Zoli Pharmaceutical and Yiling Pharmaceutical, with a focus on those with strong R&D capabilities and unique products, as well as those less affected by centralized procurement [13]

Core Insights - The China Securities Medicine and Medical Device Innovation Index (931484) shows mixed performance among its constituent stocks, with New and Achieve leading the gains at 3.63% [1] - The Medical Innovation ETF (516820) has seen a net inflow of 12.6971 million yuan over the past three days, with a peak single-day inflow of 6.1732 million yuan [1] - The current phase of brain-computer interface technology is described as an explosive period, with multiple countries, including China, accelerating their strategic positioning in global brain science [1] - AI is transitioning from a supportive role to becoming a core driver of value reconstruction and efficiency revolution in the medical industry, impacting various sectors such as medical imaging and drug development [1] Industry Overview - The Medical Innovation ETF closely tracks the China Securities Medicine and Medical Device Innovation Index, which selects 30 profitable and growth-oriented companies in the pharmaceutical and medical device sectors [2] - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray, and Hengrui Medicine, collectively accounting for 63.9% of the index [2]

Core Viewpoint - The company, Pianzihuang (600436), is currently operating normally and is committed to enhancing its performance and intrinsic value through effective management practices [1] Group 1: Company Operations - The company has confirmed that its business operations are stable and will continue to focus on management to improve performance [1] - The company emphasizes the importance of market value management and has implemented measures such as increasing dividend ratios and frequency since its listing [1] Group 2: Shareholder Engagement - The 450 million yuan special buyback loan is primarily associated with the company's controlling shareholder, Jiulongjiang Group, rather than the company itself [1] - The company plans to continue strengthening its core business and optimizing development quality to enhance long-term investment value [1]

Group 1 - The core viewpoint of the article is that the cosmetics business of Pian Zai Huang is primarily operated by its subsidiary, Fujian Pian Zai Huang Cosmetics Co., Ltd [1] - The company encourages investors to visit its official website for detailed inquiries about products of interest [1]

Core Viewpoint - The company emphasizes its commitment to strict quality control standards in the production of all its products, ensuring quality and efficacy [1] Group 1 - The company states that price differences may be influenced by various factors, including regional tax policies, transportation costs, market demand, and pricing strategies [1] - The company advises consumers to purchase products through official channels to guarantee the authenticity of its products [1]

Core Viewpoint - The company is committed to promoting its Pianzaihuang product series to a broader consumer base through multi-channel and multi-level market strategies, aiming to make its products accessible to everyday consumers [1] Group 1: Market Strategy - The company is actively expanding its mainstream chain channels and has established strategic partnerships with several leading chain stores, achieving coverage of over 100,000 terminal stores [1] - The company utilizes self-operated online and offline platforms to provide refined services, ensuring effective medication services for consumers [1] Group 2: Product Development - The company is focusing on expanding its "food and medicine homology" functional foods and health products to meet the diverse needs of different consumers [1]

Group 1 - The core viewpoint of the article is that the company Pianzaihuang has developed a capsule formulation to facilitate patient consumption, as the traditional tablet form requires manual crushing before use [2]. Group 2 - Pianzaihuang's traditional dosage form is a hard tablet that needs to be crushed before consumption [2]. - The capsule formulation was developed by filling capsules with the powdered form of the traditional tablet, approved for production in August 1991 [2].

Core Viewpoint - The company Pianzaihuang has a strong brand presence and cultural heritage, which contributes to its unique brand advantages and recognition in the market [2] Brand Recognition - Pianzaihuang has achieved significant accolades, including ranking first in the "2024 Hurun Medical Health Brand Value List" and maintaining the top position in the "Hurun China's Most Culturally Rich Brands List" for three consecutive years from 2022 to 2024 [2] - The brand value of Pianzaihuang is reported at 43.739 billion yuan, earning it the top spot in the "2024 Chinese Time-Honored Brand List" [2] Market Position - The company has established a strong reputation both domestically and internationally, being recognized as a leading exporter of traditional Chinese medicine products [2] - Pianzaihuang is referred to as a "Chinese symbol" along the Maritime Silk Road, indicating its significant role in promoting Chinese culture abroad [2] Consumer Confidence - The company's positive brand image has garnered widespread acclaim and recognition from various sectors, fostering consumer confidence in its products [2]